Free Trial

Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday

Eledon Pharmaceuticals logo with Medical background

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.28) per share for the quarter.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same quarter last year, the business earned ($1.00) EPS. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eledon Pharmaceuticals Stock Performance

Shares of NASDAQ ELDN traded down $0.08 during trading on Tuesday, hitting $3.03. The company had a trading volume of 17,660 shares, compared to its average volume of 283,628. Eledon Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $5.54. The business's 50-day moving average is $3.35 and its 200 day moving average is $3.99. The company has a market cap of $181.14 million, a P/E ratio of -1.50 and a beta of 0.08.

Wall Street Analysts Forecast Growth

Separately, Guggenheim started coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a "buy" rating and a $9.00 target price on the stock.

Get Our Latest Research Report on ELDN

Eledon Pharmaceuticals Company Profile

(Get Free Report)

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

Featured Articles

Earnings History for Eledon Pharmaceuticals (NASDAQ:ELDN)

Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?

Before you consider Eledon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.

While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines